(Q36366962)

13 August 2017

Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients (English)

1 reference

13 August 2017

1 reference

7

John Mascarenhas

1 reference

13 August 2017

Krisstina Gowin

1

1 reference

13 August 2017

Prakash Thapaliya

2

1 reference

13 August 2017

Jan Samuelson

3

1 reference

13 August 2017

Claire Harrison

4

1 reference

13 August 2017

Deepti Radia

5

1 reference

13 August 2017

Bjorn Andreasson

6

1 reference

13 August 2017

Alessandro Rambaldi

8

1 reference

13 August 2017

Tiziano Barbui

9

1 reference

13 August 2017

Catherine J Rea

10

1 reference

13 August 2017

John Camoriano

11

1 reference

13 August 2017

Amy Gentry

12

1 reference

13 August 2017

Jean-Jacques Kiladjian

13

1 reference

13 August 2017

Casey O'Connell

14

1 reference

13 August 2017

Ruben Mesa

15

1 reference

13 August 2017

14 March 2012

1 reference

13 August 2017

1 reference

13 August 2017

97

1 reference

13 August 2017

10

1 reference

13 August 2017

1570-1573

1 reference

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487558

Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487558

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487558

Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487558

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487558

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487558

Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487558

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487558

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3487558

Treatment of essential thrombocythaemia by alpha 2a interferon

5 December 2018

1 reference

12 December 2020

Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia

1 reference

12 December 2020

PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM)

1 reference

12 December 2020

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

1 reference

12 December 2020

10.3324/HAEMATOL.2011.061390

Identifiers

DOI

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

22419578

1 reference